| Not yet recruiting | 2 | 140 | Europe | Islatravir, MK-8507, MK-8591, MK-8507, Capsule, Tablet, Film-coated tablet, Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc | HIV-1 infection, HIV-1 infection, Diseases [C] - Virus Diseases [C02] | | | | |
MK-8591-013, NCT04564547: Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [] |
|
|
| Active, not recruiting | 2 | 161 | Europe, US | Islatravir, MK-8591, Ulonivirine, MK-8507, BIC/FTC/TAF, BIKTARVY®, Placebo to ISL, Placebo to Ulonivirine, Placebo to BIC/FTC/TAF | Merck Sharp & Dohme LLC | HIV-1 Infection | 12/24 | 12/24 | | |
